Elevated levels of baseline C-reactive protein (CRP), a marker of systemic inflammation and immune activation, are associated with poor treatment response to chemotherapy and adverse disease outcome in various cancers including advanced NSCLC [13,14,15,16]. This evidence concerns the gene CRP and cancer.